ArticleOpen forum infectious diseases2022
Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers.
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 69 citations in OpenAlex.
- Effects of natural killer cell depletion on innate and adaptive immune responses to COVID mRNA vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Longitudinal study of the immunological response to the SARS-CoV-2 vaccine in Instituto Português de Oncologia of Coimbra professionals.IJID regions · 2026Article
- Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions.Human vaccines & immunotherapeutics · 2025Article
- Article
- Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4.NPJ vaccines · 2025Article
- Development of a personalized digital biomarker of vaccine-associated reactogenicity using wearable sensors and digital twin technology.Communications medicine · 2025Article
- Article
- Innate immune response after BNT162b2 COVID-19 vaccination associates with reactogenicity.Vaccine: X · 2025Article
- Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity.NPJ vaccines · 2024Article
- Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis.Scientific reports · 2024Article
- Article
- Experience and side effects of COVID-19 vaccine uptake among university students: a cross-sectional survey study.Frontiers in public health · 2024Article
- Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis.Frontiers in public health · 2024Article
- Assessment of Adverse Reactions, Antibody Patterns, and 12-month Outcomes in the Mother-Infant Dyad After COVID-19 mRNA Vaccination in Pregnancy.JAMA network open · 2023Article
- Association of Self-reported Systemic Reactions Following SARS-CoV-2 Vaccination With Immunological Response in the Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE).Open forum infectious diseases · 2023Article
- Article
- Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers.Journal of clinical medicine · 2023Article
- Article
- Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination.NPJ vaccines · 2023Article
- Article
Corrections and comments
- Update of
Authors and funding
31 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThe relationship between postvaccination symptoms and strength of antibody responses is unclear. The goal of this study was to determine whether adverse effects caused by vaccination with the Pfizer/BioNTech BNT162b2 vaccine are associated with the magnitude of vaccine-induced antibody levels.
methodsWe conducted a single-center, observational cohort study consisting of generally healthy adult participants that were not severely immunocompromised, had no history of coronavirus disease 2019, and were seronegative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein before vaccination. Severity of vaccine-associated symptoms was obtained through participant-completed questionnaires. Testing for immunoglobulin G antibodies against SARS-CoV-2 spike protein and receptor-binding domain was conducted using microsphere-based multiplex immunoassays performed on serum samples collected at monthly visits. Neutralizing antibody titers were determined by microneutralization assays.
resultsTwo hundred six participants were evaluated (69.4% female, median age 41.5 years old). We found no correlation between vaccine-associated symptom severity scores and vaccine-induced antibody titers 1 month after vaccination. We also observed that (1) postvaccination symptoms were inversely correlated with age and weight and more common in women, (2) systemic symptoms were more frequent after the second vaccination, (3) high symptom scores after first vaccination were predictive of high symptom scores after second vaccination, and (4) older age was associated with lower titers.
conclusionsLack of postvaccination symptoms after receipt of the BNT162b2 vaccine does not equate to lack of vaccine-induced antibodies 1 month after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.